These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17321668)

  • 41. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Value of contrast-enhanced sonographic micro flow imaging for prostate cancer detection with t-PSA level of 4-10 ng/mL.
    Guo YF; Li FH; Xie SW; Xia JG; Fang H; Li HL
    Eur J Radiol; 2012 Nov; 81(11):3067-71. PubMed ID: 22647421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation.
    Sciarra A; Maggi M; Fasulo A; Salciccia S; Gentile V; Cattarino S; Gentilucci A
    Urologia; 2017 Aug; 84(3):158-164. PubMed ID: 28430341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Value of power doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer.
    Sauvain JL; Palascak P; Bourscheid D; Chabi C; Atassi A; Bremon JM; Palascak R
    Eur Urol; 2003 Jul; 44(1):21-30; discussion 30-1. PubMed ID: 12814671
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial.
    Kattan MW; Earnshaw SR; McDade CL; Black LK; Andriole GL
    Appl Health Econ Health Policy; 2011 Sep; 9(5):305-15. PubMed ID: 21875161
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
    Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN PATIENTS RECEIVING DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA].
    Endo T; Kamiya N; Yano M; Oka R; Lee FC; Utsumi T; Kamijima S; Nishimi D; Takanami M; Hiruta N; Suzuki H
    Nihon Hinyokika Gakkai Zasshi; 2015 Jul; 106(3):156-62. PubMed ID: 26419072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score.
    Nelson ED; Slotoroff CB; Gomella LG; Halpern EJ
    Urology; 2007 Dec; 70(6):1136-40. PubMed ID: 18158034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival.
    Ismail M; Petersen RO; Alexander AA; Newschaffer C; Gomella LG
    Urology; 1997 Dec; 50(6):906-12. PubMed ID: 9426722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies.
    Taymoorian K; Thomas A; Slowinski T; Khiabanchian M; Stephan C; Lein M; Deger S; Lenk S; Loening SA; Fischer T
    Anticancer Res; 2007; 27(6C):4315-20. PubMed ID: 18214038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing.
    Bostwick DG; Qian J; Drewnowska K; Varvel S; Bostwick KC; Marberger M; Rittmaster RS
    Urology; 2010 Jun; 75(6):1406-10. PubMed ID: 19942263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study).
    Inoue T; Yoshimura K; Terada N; Tsukino H; Murota T; Kinoshita H; Kamoto T; Ogawa O; Matsuda T
    Int J Urol; 2021 Aug; 28(8):849-854. PubMed ID: 34008275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy?
    Remzi M; Dobrovits M; Reissigl A; Ravery V; Waldert M; Wiunig C; Fong YK; Djavan B;
    Eur Urol; 2004 Oct; 46(4):451-6. PubMed ID: 15363559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The role of power Doppler-guided prostatic biopsy in the diagnosis of prostate cancer].
    Okihara K; Kojima M; Nakanouchi T; Okada K; Miki T
    Hinyokika Kiyo; 1999 Aug; 45(8):559-63. PubMed ID: 10500963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endorectal color doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: correlation with radical prostatectomy findings.
    Cornud F; Hamida K; Flam T; Hélénon O; Chrétien Y; Thiounn N; Correas JM; Casanova JM; Moreau JF
    AJR Am J Roentgenol; 2000 Oct; 175(4):1161-8. PubMed ID: 11000183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial.
    Grubb RL; Andriole GL; Somerville MC; Mahoney C; Manyak MJ; Castro R
    J Urol; 2013 Mar; 189(3):871-7. PubMed ID: 23021996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Status of transrectal ultrasound imaging of the prostate.
    Aigner F; Mitterberger M; Rehder P; Pallwein L; Junker D; Horninger W; Frauscher F
    J Endourol; 2010 May; 24(5):685-91. PubMed ID: 20433367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers.
    Kuligowska E; Barish MA; Fenlon HM; Blake M
    Radiology; 2001 Sep; 220(3):757-64. PubMed ID: 11526279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.